John O'Bryan to Proto-Oncogene Proteins p21(ras)
This is a "connection" page, showing publications John O'Bryan has written about Proto-Oncogene Proteins p21(ras).
Connection Strength
1.804
-
Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020 10 30; 48(5):1831-1841.
Score: 0.687
-
Targeting the a4-a5 interface of RAS results in multiple levels of inhibition. Small GTPases. 2019 09; 10(5):378-387.
Score: 0.564
-
Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket. Proc Natl Acad Sci U S A. 2022 10 25; 119(43):e2204481119.
Score: 0.197
-
Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nat Commun. 2021 05 11; 12(1):2656.
Score: 0.178
-
Targeting the KRAS a4-a5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases. 2022 Jan; 13(1):114-127.
Score: 0.178